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Background: Acute stent recoil has been often observed following stent delivery balloon deﬂation in
coronary arteries and the recoil rate varies by stent design. Accordingly, the purpose of the present study
was to evaluate the impact of stent designs on acute stent recoil after new generation drug-eluting stent
implantation.
Methods and results: A total of 154 lesions [56 treated with biolimus-eluting stent (BES), 46 with cobalt
chromium everolimus-eluting stent (CoCr-EES), and 52 with platinum chromium everolimus-eluting
stent (PtCr-EES)] were evaluated. Quantitative coronary angiography was used to measure the minimal
lumen diameter (MLD). MLD1 was deﬁned as a MLD of complete expansion of the last stent delivery
balloon at the highest pressure. MLD2 was deﬁned as a MLD immediately after the last stent deliv-
ery balloon deﬂation. Acute stent recoil was determined by the calculation as (MLD1−MLD2)/MLD1.
Acute stent recoil was signiﬁcantly higher in the CoCr-EES group versus the BES group and PtCr-EES
group (10.1±6.9%, 6.7±5.5%, and 6.5±4.8%, respectively, p=0.01). Multivariate linear regression anal-
ysis demonstrated that the use of CoCr-EES and the number of stent delivery balloon inﬂations were
independent predictors of acute stent recoil (r=0.26, ˇ =0.21, p=0.01 and r=−0.51, ˇ =−0.58, p<0.01,
respectively).
Conclusion: Acute stent recoil occurred more frequently with the CoCr-EES compared with both BES and
PtCr-EES. Strategieswithmultipleballoon inﬂationmightbeneeded toovercomethis recoil phenomenon.
© 2ntroduction
In percutaneous coronary intervention (PCI), coronary stents
avebeenusedas the standard for treatmentof coronary arterydis-
ase. They provide vessel wall scaffolding and prevent acute recoil
nd restenosis of target sites compared with only balloon angio-
lasty [1]. In the drug-eluting stent (DES) era, despite advances
n polymer and drug technology, the underlying stent platform
emains a key determinant of clinical outcome. A clear under-
tanding of stent design and the differences between various stent
latforms are of increasing importance for the interventional car-
iologist. Reduction in stent strut thickness has been associated
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with improved stent deliverability, improved procedural outcome,
and lower rates of subsequent restenosis and thrombosis [2–4]. On
the other hand, a reduction in the strut thickness leads to elastic
stent recoil [5,6]. The ideal stent is typically considered as one that
is highly deliverable with thin-strut and ﬂexible design but with
high radial strength and minimal elastic recoil. Acute stent recoil
has often been observed following stent delivery balloon deﬂation
in coronary arteries. Some studies have shown that the incom-
plete delivery balloon expansion and post-deﬂation stent recoil
are the most important predictors of the post-procedure sever-
ity of the residual lesion [7,8]. Subsequent studies have shown
that acute stent recoil often occurs and the recoil rate varies by
stent design [5,6,9]. Althoughplatinumchromiumstents have been
used widely, the magnitude of acute stent recoil with regard to
these three major properties of metal stent has not been fully
analyzed.
Accordingly, the aim of the present study was to investigate the
degree of acute stent recoil of three new generation DESs by means
of quantitative coronary angiography.
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tudy population and stent type
This study was a retrospective, single-center, and non-
andomized one. A series of 154 lesions of 141 patients undergoing
oronary intervention using three different types of new gener-
tion DES of the following designs were analyzed: (1) biolimus
luting stent (BES) – 135mthick, stainless steel platform,NOBORI
tent, TERUMO, Tokyo, Japan; (2) cobalt chromium everolimus-
luting stent (CoCr-EES) – 81m thick, cobalt chromium platform,
IENCE V stent, Abbott Vascular, Santa Clara, CA, USA; and (3) plat-
numchromiumeverolimus-eluting stent (PtCr-EES)–81mthick,
latinum chromium platform, PROMUS ELEMENT stent, Boston
cientiﬁc, Natick, MA, USA. The patients were classiﬁed into three
roups by stent design; a BES group (51 patients, 56 lesions); a
oCr-EES group (43 patients, 46 lesions); and a PtCr-EES group
47 patients, 52 lesions). PCI was performed according to standard
ethods. The decision to perform pre-dilation and post-dilation
alloon inﬂations, as well as the use of intravascular ultrasound,
as made at the discretion of the operator.
Exclusion criteria included chronic total occlusion (eight
esions), severe calciﬁed lesions requiring pre-treatment by rota-
ional atherectomy (four lesions), in-stent restenosis lesions (20
esions), and inadequate angiography needed to calculate acute
tent recoil (15 lesions).
We obtained informed consent from all patients for PCI and
ata to be used for analyses. The study was in agreement with the
uidelines of the ethics committee of our institution.
uantitative angiographic analysis and deﬁnitions
Angiograms were reviewed as a single group by two experi-
nced observers blinded to the clinical information. Quantitative
oronary analysis (QCA) was performed using the Cardiovascular
easurement System. Contrast-ﬁlled guiding catheters were used
ormagniﬁcation calibration. Each angiographic sequencewas pre-
eded by intracoronary injection of nitroglycerin. In this study, QCA
asused tomeasure theminimal lumendiameter (MLD), reference
essel diameter, and percent diameter stenosis. In addition to the
aseline and post-procedure images, two images were analyzed
or acute stent recoil assessment. MLD1 was deﬁned as a MLD of
omplete expansion of the last stent delivery balloon at the high-
st pressure (Fig. 1A). MLD2 was deﬁned as a MLD immediately
fter the last stent delivery balloon deﬂation (Fig. 1B). These two
ig. 1. Method of acute stent recoil assessment. MLD1 was deﬁned as a minimum lume
ighest pressure (A). MLD2 was deﬁned as a MLD immediately after the last stent deliver
rojection. White solid lines indicate the MLD within the analyzed segment.ogy 64 (2014) 347–352
images were analyzed in the same angiographic projection. The
percentage of acute stent recoil was determined by the calculation
as (MLD1−MLD2)/MLD1 [1,7,8,10].
In the study, diabetes was deﬁned as a fasting plasma glu-
cose concentration >126mg/dl, a randomized plasma glucose
concentration >200mg/dl, hemoglobin A1c levels ≥6.5%, and/or
anti-hyperglycemic treatment. Hypertension was deﬁned as the
presence of systolic blood pressure >160mmHg and/or diastolic
blood pressure >90mmHg, and/or anti-hypertensive treatment.
Dyslipidemia was deﬁned as the presence of low-density lipopro-
tein levels ≥140mg/dl, triglyceride levels ≥150mg/dl, and/or
high-density lipoprotein cholesterol levels <40mg/dl, and/or if
patients used any anti-dyslipidemic medication.
Statistical analysis
Statistical analysis was performed using the SPSS 18.0 soft-
ware program (SPSS Inc., Chicago, IL, USA). Data are expressed as
mean± SD for continuous variables and as percentages for discrete
variables. Group differences were assessed by Student’s unpaired
t test, Mann–Whitney U test or one-way factorial analysis of vari-
ance (ANOVA) for continuous variables, and 2 analysis or Fisher’s
exact test for categorical variables, as appropriate. When a signif-
icant difference was present by ANOVA, intergroup comparisons
were made by Scheffe’s multiple comparison tests. Independent
predictors for the occurrence of acute stent recoil were determined
by multivariate linear analyses. Clinical values were entered into
the univariate linear analysis, and of them, the predictive values
with p<0.1 in the univariate linear analyses were entered into a
multivariate linear analysis. A two-sided p-value <0.05 was con-
sidered statistically signiﬁcant.
Results
Baseline clinical and anatomic characteristics
Table 1 shows the baseline clinical characteristics. There was
no signiﬁcant difference among the three groups in terms of clini-
cal characteristics. Baseline anatomic characteristics are shown in
Table 2. Location of target lesion and lesion characteristics were
similar among the three groups.Table 3 compares the procedural characteristics andQCA results
of the three study groups. In the CoCr-EES group, lesion length was
signiﬁcantly shorter than that in the other two groups. As a result,
CoCr-EESgroupusedsigniﬁcantly shorter stents comparedwith the
n diameter (MLD) of complete expansion of the last stent delivery balloon at the
y balloon deﬂation (B). These two images were analyzed in the same angiographic
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Table 1
Baseline clinical characteristics.
BES CoCr-EES PtCr-EES p value
No. of patients 51 43 47 –
No. of lesions 56 46 52 –
Male (%) 88.2 81.4 76.6 0.32
Diabetes (%) 58.8 48.8 51.1 0.59
Hypertension (%) 68.6 55.8 74.5 0.16
Hypercholesterolemia (%) 52.9 53.5 44.7 0.63
Current smoking (%) 64.7 53.5 63.8 0.48
Clinical status (%)
Stable angina 52.6 72.0 68.1 0.11
Unstable angina 17.6 14.0 14.9 0.87
Acute myocardial infarction 15.7 14.0 17.0 0.92
Recent myocardial infarction 3.9 0 0 0.17
Values are expressed as percentages.
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Table 2
Baseline anatomic characteristics.
BES CoCr-EES PtCr-EES p value
No. of lesions 56 46 52 –
Location of target lesion (%)
Right coronary 32.1 41.3 32.7 0.57
Left anterior descending 44.6 32.6 50.0 0.21
Circumﬂex 17.9 19.6 13.5 0.70
Left main 5.4 6.5 3.8 0.84
Bifurcation (%) 21.4 17.4 30.8 0.27
Tortuosity (%) 21.4 13.0 26.9 0.24
Calciﬁcation (%) 23.2 17.4 19.2 0.75
Eccentric (%) 50.0 56.5 69.2 0.12
Thrombus (%) 5.4 10.9 17.3 0.14
Diffuse (%) 32.1 47.8 38.5 0.27
Lesion angle >45◦ (%) 16.1 13.0 13.5 0.89
Type B2/C (%)a 58.9 63.0 61.5 0.91
BES, biolimus-eluting stent; CoCr-EES, cobalt chromium everolimus-eluting stent;
PtCr-EES, platinum chromium everolimus-eluting stent.
Values are expressed as percentages.
Discussion
T
A
B
VES, biolimus-eluting stent; CoCr-EES, cobalt chromium everolimus-eluting stent;
tCr-EES, platinum chromium everolimus-eluting stent.
ther two groups. At baseline and after procedure, there were no
igniﬁcant differences in reference diameter and MLD. Frequency
f pre-dilatation and post-dilatation was similar among the three
roups.
Fig. 2 shows the comparison of acute stent recoil among the
hree groups. There was no signiﬁcant difference between BES
roup and PtCr-EES group (p=0.59). On the other hand, patients
reated with CoCr-EES showed signiﬁcantly greater acute stent
ecoil (10.1±6.9%) compared with those of PtCr-EES (6.5±4.8%)
nd BES (6.7±5.5%) groups (p=0.01).
Fig. 3 shows the comparison of the number of the stent
elivery balloon inﬂations and acute stent recoil. In the BES,
hree-time-inﬂation group showed signiﬁcantly lower acute stent
ecoil (11.50±7.16%) compared with one-time-inﬂation and two-
ime-inﬂation groups (3.39±3.48% and 6.84±3.96%; p=0.01
nd p=0.01, respectively) (Fig. 3A). In the CoCr-EES, one-time-
nﬂation group showed signiﬁcantly greater acute stent recoil
11.67±4.61%) compared with two-time-inﬂation and three-
ime-inﬂation groups (9.14±4.78% and 5.20±6.60%; p<0.01 and
able 3
ngiographic and procedural data.
BES
No. of lesions 56
Procedural characteristics
Stent length (mm) 21.8±5.5
Stent size (mm) 2.84±0.39
No. of stent delivery balloon inﬂations 2.1±0.7
Post-dilatation balloon size (mm) 3.02±0.40
Balloon/artery ratio 1.30±0.18
Pre-dilatation (%) 71.4
Post-dilatation (%) 89.3
Quantitative coronary angiography
At baseline
Reference diameter (mm) 2.25±0.55
MLD (mm) 0.74±0.37
Diameter stenosis (%) 68.0±13.3
Lesion length (mm) 21.4±13.3
Intra-procedure
MLD1 (mm) 2.66±0.51
MLD2 (mm) 2.47±0.43
After procedure
In-stent
Reference diameter (mm) 2.96±0.57
MLD (mm) 2.67±0.59
Diameter stenosis (%) 9.6±9.9
ES, biolimus-eluting stent; CoCr-EES, cobalt chromium everolimus-eluting stent; PtCr-E
alues are expressed as percentages or means± SD.
† p<0.05 vs. BES.
‡ p<0.05 vs. PtCr-EES.a Type of lesion was determined according to American College of
Cardiology/American Heart Association classiﬁcation.
p<0.01, respectively) (Fig. 3B). In the PtCr-EES, one-time-inﬂation
group showed signiﬁcantly greater acute stent recoil (9.60±4.90%)
comparedwith two-time-inﬂation and three-time-inﬂationgroups
(5.21±4.36% and 4.40±3.11%; p=0.02 and p<0.01, respectively)
(Fig. 3C).
The results of multivariate linear regression analysis are shown
in Table 4. Multivariate models demonstrated that the use of CoCr-
EES and the number of stent delivery balloon inﬂations were
independent predictors of acute stent recoil (r=0.26, ˇ =0.21,
p=0.01 and r=−0.51, ˇ =−0.58, p<0.01, respectively).The major ﬁndings of the present study are as follows: (1) the
greatest acute stent recoil was observed in the case of the CoCr-EES
CoCr-EES PtCr-EES p value
46 52 –
18.6±5.9† ,‡ 20.4±6.3 0.02
2.85±0.37 2.88±0.38 0.83
1.9±0.6 2.0±0.8 0.11
3.08±0.48 3.06±0.48 0.79
1.33±0.26 1.30±0.20 0.74
54.3 75.0 0.07
80.4 96.2 0.06
2.30±0.45 2.27±0.44 0.88
0.82±0.37 0.67±0.42 0.18
65.0±13.3 71.4±16.4 0.11
15.4±8.0† ,‡ 22.2±11.4 0.01
2.76±0.38 2.65±0.40 0.41
2.49±0.40 2.48±0.40 0.99
2.89±0.44 2.91±0.40 0.76
2.52±0.42 2.56±0.40 0.25
12.9±7.3 12.4±7.3 0.09
ES, platinum chromium everolimus-eluting stent; MLD, minimal lumen diameter.
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Fig. 2. Comparison of acute stent recoil among three groups. BES, biolimus-eluting
s
p
Table 4
Multivariate linear regression analyses for acute stent recoil.
r ˇ p
Number of inﬂations −0.51 −0.48 <0.01
F
stent group; CoCr-EES, cobalt chromium everolimus-eluting stent group; PtCr-EES,
latinum chromium everolimus-eluting stent group.
ig. 3. Comparisonof thenumberof the stentdeliveryballoon inﬂations andacute stent rec
tent (CoCr-EES) group; and (C) platinum chromium everolimus-eluting stent (PtCr-EES)Use of CoCr-EES 0.26 0.21 0.01
CoCr-EES, cobalt chromium everolimus-eluting stent.
among three new generation DESs and (2) strategies with multiple
balloon inﬂation were associated with a decreased risk of acute
stent recoil.
The phenomenonof acute stent recoil has been recognized since
the ﬁrst implantation in human coronary arteries. In previous clini-
cal trials, acute stent recoil variedbetween4.3%and21.3% [7,10,11].
Many variations of the original concept of coronary stent have been
introduced by the medical industry. In normal porcine coronary
arteries, acute stent recoil was found to be one of the most impor-
tant determinants of the post-procedure severity of the residual
lesion. If acute stent recoil canbe reduced, thismayhave a favorable
effect on acute gain [11].
In this study, we analyzed the three different types of new
generation DESs (BES, CoCr-EES, and PtCr-EES). CoCr-EES is a new
generation DES based on the cobalt chromium platform. PtCr-EES
oil. (A) Biolimus-eluting stent (BES) group; (B) cobalt chromiumeverolimus-eluting
group.
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s based on the platinum chromium platform, which has the same
trut thickness as CoCr-EES. BES is based on the stainless steel
latform. Radial strength is a quantitative measure of stent scaf-
olding strength and the ability of a stent to maintain the vessel
umen. Compared with the BESs (135m), the CoCr-EESs have
hinner struts (81m) and better ﬂexibility and deliverability [12].
owever, reduced strut thickness of CoCr-EES might decrease the
tent’s radial force, leading to acute stent recoil. On the other
and, despite the fact that PtCr-EES has the same strut thickness
s the CoCr-EES, PtCr-EES could gain higher radial strength than
he CoCr-EES. As a result, PtCr-EES could have lower acute stent
ecoil [5,13]. The results of our study extend the previous obser-
ations and document the fact that acute stent recoil is more
orrelated with stent design and materials compared with stent
trut thickness. A previous study showed that reduced strut thick-
ess decreased the radial strength, leading to more acute stent
ecoil [9]. However, these studies included stainless steel and
obalt chromium platforms, but not platinum chromium platform.
adial strength of the thin strut PtCr-EES remains similar to that of
he stainless steel stent with the thicker strut [13,14]. Low recoil
as clinically desirable to reduce the risk of malapposition and
estenosis.Malappositionmay increase the risk of subsequent stent
hrombosis [15].
Stent under expansion was associated with stent thrombosis
nd restenosis after implantation of DES [16–19]. Stent expansion
ight be affected by several lesion or procedural characteris-
ics, such as reference vessel diameter, MLD, maximum balloon
ressure, pre-lesion modiﬁcation, and the presence of lesion
alciﬁcation [20,21]. In our study, lesions of chronic total occlu-
ion, in-stent restenosis, and severe calciﬁcation, which estimated
igher stent recoil, were excluded. Our multivariate predictor of
cute stent recoil was the use of CoCr-EES. In contrast, strategies
ithmultiple balloon inﬂationwere related to reduced risk of acute
tent recoil. Interestingly, the number of stent delivery balloon
nﬂations was signiﬁcantly associated with the reduction of acute
tent recoil. Furthermore, the difference varied by stent design.
n the BES, three-time-inﬂation group showed signiﬁcantly lower
cute stent recoil comparedwith one-time-inﬂation and two-time-
nﬂation groups. On the other hand, in the CoCr-EES and PtCr-EES,
ne-time-inﬂation group showed signiﬁcantly greater acute stent
ecoil compared with two-time and three-time-inﬂation groups. In
ll three types of stent, three-time-inﬂation strategy leads to lower
cute stent recoil rate compared with one-time-inﬂation strategy.
here were a few studies about relationship between the number
f stent delivery balloon inﬂations and stent expansion [22,23].
he mechanism responsible for better stent expansion by multi-
le numbers of stent delivery balloon inﬂations remains unknown.
tent was folded and attached to the stent delivery balloon before
tent delivery balloon inﬂation; therefore, additional force may be
eeded to expand stent strut cells and connection when the stent
elivery balloon is ﬁrst inﬂated. Few studies have reported the
elationship between balloon inﬂation time and stent expansion.
awasaki et al. [23] indicated that 60-s delivery balloon inﬂation
ime may result in more optimal stent expansion. Asano et al. [24]
eported that better stent expansion was obtained by 60-s inﬂation
ompared with 10-s inﬂation. Our ﬁndings were consistent with
uch previous results. However if we performed such a long inﬂa-
ion, the patient might feel chest pain and electrocardiogram may
how ST segment change. A multiple number of inﬂation strategy
ight be useful in PCI for critical lesions especially left main coro-
aryartery, proximalpart of left descendingartery, and jeopardized
ollateral coronary artery. In our study, unfortunately, both dura-
ion of stent delivery balloon inﬂation time and the number of stent
eliveryballoon inﬂationsweredependentonoperators. Therefore,
ptimal durationof inﬂation timeand thenumberof inﬂationshave
een unclear. Further investigations are needed in this context.ogy 64 (2014) 347–352 351
This study has several important limitations. First of all, it was
not randomized and was a retrospective study. The choice of the
stents was left to the discretion of the operator, which may have
introduced some bias in the choice of a particular type of stent
based on the characteristics of the diseased vessel. The PCI proce-
dures such as the use of intravascular ultrasound, pre-dilatation,
and post-dilatation were all held at the discretion of each operator.
Second, all of the measurements were calculated by QCA. There-
fore, small quantitative changes may not have been evaluated. The
positions of MLD of the balloon and stent are usually different.
Third, post-dilatation using a different larger size balloon might
overcome stent recoil. Final, the long-termoutcomes, including the
stent restenosis rate, target lesion revascularization rate, and other
major adverse cardiac events, were not examined because only the
intra-procedure data were examined in this study.
In conclusion, acute stent recoil more frequently occurred with
the CoCr-EES, which is made of cobalt chromium with 81m strut
thickness. The PtCr-EES which is made of platinum chromium with
81m strut thickness showed acute stent recoil similar to the BES
which ismadeof stainless steelwith135mstrut thickness. Strate-
gies with multiple balloon inﬂations are needed to overcome this
recoil phenomenon. Our data have signiﬁcant clinical implication
regarding the strategy for optimal stent implantation.
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